Abstract Adoptive transfer of antiviral eVector or memory CD8 T cells is a therapeutic option for preventing acute cytomegalovirus (CMV) disease after primary or recurrent infection in immunocompromised recipients of hematopoietic stem cell transplantation (HSCT) aimed at curing hematopoietic malignancies. Preclinical research in murine models has demonstrated the power of CD8 T-cell-based preemptive immunotherapy and has encouraged clinical trials that gave promising results. The clinical evidence, however, is based primarily on statistical analyses indicating a reduced incidence of CMV-associated complications. Here, we will brieXy review the data obtained from the murine model showing that CD8 T cells derived from CMVimmune donors and administered either as peptide-selected cytolytic T lymphocyte lines or after ex vivo puriWcation by T-cell-receptor-speciWc cell sorting can indeed prevent CMV-mediated histopathology and multiple organ failure.
Introduction and clinical background
Hematopoietic stem cell transplantation (HSCT) combined with donor lymphocyte infusion (DLI) is a promising therapeutic option against hematologic malignancies [1] (for more comprehensive information, see also the contribution by Erlach et al. in this issue of MMI). Infection of the transiently immunocompromised HSCT recipient with human CMV (hCMV) prior to the immune reconstitution is a serious complication that can cause bone marrow engraftment failure and multiple organ CMV disease, with interstitial pneumonia being the predominant clinical manifestation associated with morbidity and mortality [2, 3] . Interestingly, although one would predict an additive risk of virus recurrence in the double-positive constellation, clinical experience tells us that the risk of CMV recurrence and disease is lower than in the D ¡ R + constellation, a Wnding attributed to transfer of preexisting donor immunity (for an overview, see [4] ). Since HLA-matched allogeneic HSCT (allo-HSCT) is often combined with DLI to enhance graft-versus-leukemia (GvL) reactivity, it is an obvious strategy to prevent CMV reactivation and disease in the CMV-positive recipient by adding enriched virusspeciWc CD8 T cells derived from a CMV-immune donor [5, 6] . Ideally, the CD8 T cell donor should also be the donor of HSCT, as in such a constellation, a Wt in viral peptide presentation between donor and recipient is guaranteed by the HLA matching that is done anyway for the HSCT. Preferably, of course, donors should be CMV-negative but CMV-immune, which implies vaccination of CMV-negative donors. Currently, no CMV vaccine has been licensed, but addressing the CMV-negative HSCT donor is one impetus for the development of a non-infectious CMV vaccine, such as a recombinant subviral particle vaccine ( [7] ; see also the contribution by Mersseman et al. in this issue of MMI).
Cell-based preemptive immunotherapy of CMV disease in the immunocompromised host by adoptive transfer of CMV-speciWc eVector or memory CD8 T cells was Wrst shown in the murine model [8] [9] [10] [11] , before translational research led to promising clinical trials, showing a reduced incidence of CMV infection and disease in patients who received hCMV-speciWc eVector CD8 T cells selected and ampliWed by restimulation of donor memory CD8 T cells in cell culture [12] [13] [14] . So far, however, CD8 T cell-based antiviral immunotherapies have not entered clinical routine due to exceedingly high cell numbers required in the initial clinical trials and the associated great logistic and regulatory demands [6] . More recent eVorts, therefore, were aimed at further developing this approach by improved cell culture methods generating more eYcient short-term CD8 T cell lines with broader epitope-speciWcity and higher avidity [15, 16] ; Wnally, in accordance with Wndings in the murine model [17] , clinical studies using T cell receptor (TCR)-based sorting of CD8 T cells derived from CMVimmune donors by employing MHC-peptide multimers showed a superior antiviral eYcacy of ex vivo memory CD8 T cells, providing protection after transfer of reasonably low cell numbers [18] .
Murine model of cytomegalovirus immunotherapy

Principles and historical perspective
As discussed in several articles in this issue of MMI, CMVs are host species-speciWc as a result of a sophisticated evolutionary adaptation to their respective mammalian host; as a consequence, hCMV cannot be studied in animal models (see in particular the contribution by Powers et al. in this issue of MMI). On the other hand, the dilemma is that many urgent questions concerning CMV biology, pathogenesis, and disease prevention and therapy cannot be addressed in vivo in humans, but require experimental models for providing "proof of concept". Clearly, a properly designed model should always ask those questions that really need a model for the answer. The murine model is the most advanced, as here we have the unique possibility to combine genetic engineering of the virus, that is murine CMV (mCMV), with genetic engineering of the host to ask and answer otherwise not addressable questions. The contribution by Sacher et al. in this issue of MMI gives us a splendid example of how virus spread and dissemination can be studied by cell-type speciWc recombination of a Xoxed reporter virus in mice that express Cre recombinase under the control of cell-type speciWc promoters. Tracing the recombined mCMV mutant by means of the expression of enhanced green Xuorescent protein (eGFP) has led to the astounding Wnding that the major virus producing cell type, namely the hepatocyte, does not contribute to virus dissemination to other organs by secondary viremia, a Wnding that challenges fundamental concepts of virology [19] .
One can always argue about the validity of animal models, in particular in face of limited genomic and proteomic homology between diVerent CMV species and the existence of a large array of private genes not shared between them but thought to reXect host adaptation genes. As we have discussed previously [20, 21] (see also the article by Erlach et al. in this issue of MMI), however, adaptation of CMV species to their respective hosts has apparently led to evolutionary convergence, so that diVerent virus-host pairs are biologically more similar than genetic diVerences between the viruses might suggest. Therefore, even if it were possible, studying heterologous virus-host pairs with a disrupted virus-host adaptation would not be recommendable.
For the speciWc problem of CD8 T cell-based immunotherapy of CMV disease in the immunocompromised host, the murine model has already shown its predictive value in that it has paved the way for clinical trials (reviewed in [20, 22] ). SpeciWcally, CD8 T cells were conWrmed as being the primary antiviral eVector cells during acute infection for preventing CMV organ disease. Moreover, the relevance of the regulatory immediate-early (IE) proteins as antigens in CMV immunity, originally described for mCMV in the BALB/c mouse model [10, 23, 24] (for a review, see [22] ) and doubted for almost two decades in hCMV immunology, has eventually proven to be valid for a broad range of HLA haplotypes in the human population [25] [26] [27] [28] [29] .
From a historical perspective, it were Starr and Allison [30] and Ho [31] , who were the Wrst to show that adoptive transfer of mCMV-experienced lymphocytes can protect recipients against acute CMV infection and CMV-associated mortality. The protective lymphocytes were either cytotoxic cells generated in cell culture by restimulation of memory spleen cells with infected Wbroblasts or ex vivo lymphocytes derived from the spleen of acutely infected mice between days 6 and 14. The protective eVect was MHC (H-2)-restricted and was abrogated by depletion of theta antigen (Thy-1, CD90)-positive cells indicating that the protective cells were actually T lymphocytes. Adoptive cell transfer as an experimental immunotherapy of CMV disease in the immunocompromised host was introduced by the group of Ulrich H. Koszinowski [8] (for reviews see [20, 22] ), identifying the CD8 T lymphocytes as the protective T cell subset in this preclinical model. The early studies in the immunocompromised host model were short-term protection assays in recipients subjected to a sublethal hematoablative treatment not yet involving HSCT. As shown in subsequent studies, in the syngeneic [32] [33] [34] and in the single MHC class-I disparate [35] HSCT models, endogeneous reconstitution of CD8 T cells terminates acute infection and prevents CMV organ disease. Combining endogenous reconstitution by HSCT with the transfer of CMV-speciWc CD8 T cells as a preclinical correlate for HSCT combined with DLI (see "Introduction") was found to improve the eYcacy of CMV control. Notably, immunotherapy in the HSCT model was found not only to speed up the control of acute infection but also to limit the establishment of viral latency and thus to reduce the risk of virus recurrence [36] . More recently, eVector-memory CD8 T cells (CD8-T EM ) present in latently infected lungs, after resolution of acute mCMV infection in a syngeneic HSCT model, were shown to also maintain viral latency by sensing of early stages of reactivated gene expression [37, 38] (reviewed in [21] ).
Model design and experimental regimen
The basic experimental regimen of epitope-speciWc immunotherapy in the HSCT model of CMV infection is illustrated in Fig. 1 . Memory CD8 T cells (CD8-T M ), usually comprising a mixture of CD62L high central memory cells (CD8-T CM ) and CD62L low CD8-T EM , were derived from the spleen of latently infected donors. We prefer using CD8-T M , since clinical HSCT/DLI is, obviously, never done with acutely infected donors, so that using CD8-T M is the model, which has a clinical correlate. Besides naïve CD8 T cells and CD8-T M of unrelated speciWcities primed by previous episodes of multiple casual antigen encounters, the CD8 T cell population of a latently infected donor includes polyclonal mCMV-speciWc CD8-T M carrying TCRs each of which recognizes its cognate MHC-peptide complex. CD8-T M speciWc for diVerent mCMV epitopes are present in the CD8 T cell population with diVerent prevalences, thus deWning antigenic peptides as being immunodominant, intermediate, or subdominant (see Table 1 , [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] for the example of the BALB/c mouse model representing the MHC H-2 d haplotype). Though transfer of polyspeciWc CD8-T M is a favored option that accounts for possible mutations in single epitopes of the virus variant infecting the recipient, recent work has documented that adoptive CD8 T cell control is not generally improved by combining protective epitope speciWcities [48] . For evaluating the protective potential of a single epitope, an epitope-speciWc eVector CD8 T cell (CD8-T E ) population can be generated in form of a cytolytic T lymphocyte line (CTLL) by repeated in vitro restimulation with antigen-presenting cells (APC), selectively expressing the epitope or loaded exogenously with the respective synthetic peptide. Alternatively, epitope-speciWc CD8-T M can be puriWed directly from the polyspeciWc population by TCR-based cell sorting employing MHC-peptide multimers.
We have previously deWned two basic models for experimental immunotherapy of CMV disease [8, 9] : a model for preemptive therapy (Fig. 1a) and a model for therapy (Fig. 1b) . In essence, the diVerence lies in the time of adoptive transfer relative to the time of infection.
For preemptive therapy, CD8 T cells are administered on the day of infection when the virus still has to disseminate from an initial local site of infection, the "portal of entry"-for instance the footpad tissue in the case of intraplantar/ subcutaneous infection-to the distant organ sites of CMV pathogenesis, such as the liver, the spleen, the lungs, the kidneys, the adrenal glands, and the gastrointestinal tract. Thus, CD8 T cells might already interfere with dissemination, which is thought to involve cells used as vehicles, such as late myeloid progenitors and their diVerentiation lineage progeny, namely macrophages and dendritic cells (for reviews see [49, 50] ). Recently, mCMV gene M36 has been identiWed to be important for dissemination by its function to prevent apoptosis in infected cells, in macrophages in particular [51] [52] [53] .
By contrast, in the therapy model, CD8 T cells are administered with a delay of 6 days, a time when virus disseminated from the portal of entry has already colonized the target organs of CMV disease. SpeciWcally, as recently shown by Erlach et al. [54] for the infection of the liver, infected hepatocytes become visible by immunohistological detection of intranuclear IE1 protein at »4 days after intraplantar infection, followed by a log-linear intrahepatic virus spread between hepatocytes and also to endothelial cells and KupVer-type macrophages, eventually leading to plaque-like lesions in the liver parenchyma [20] . Thus, in this model, transferred CD8 T cells have to cope with an established, though still early, tissue infection.
Key results of the murine model
Although »ten-fold higher cell numbers were needed in the therapy model compared to the preemptive therapy model [8, 9] , the results of these studies collectively allow us to conclude that the protective eVect of CD8 T cells is not limited to the prevention of virus dissemination to organ sites of pathogenesis but that CD8 T cells can attack infected tissue cells and prevent the development of a clinically signiWcant viral histopathology (Fig. 2) .
That protective CD8 T cells operate within tissue by forming focal inWltrates that conWne and eventually resolve acute infection is impressively documented by two-color immunohistology detecting CD3 -positive T cells in close proximity to infected cell foci-and only there! This was shown for the liver in immunocompromised mice after CD8 T cell transfer [35] (see also the accompanying article by Böhm et al. in this issue of MMI) as well as after recruitment of CD8 T cells in immunocompetent Alb-Cre and Tie2-Cre mice after cell-type speciWc recombination of eGFP-expressing reporter virus in hepatocytes and endothelial cells, respectively [19] . Likewise, in the HSCT model, protective focal inWltration was prominent in the lungs after endogenous lympho-hematopoietic reconstitution [34] .
Another key Wnding of predictive value for clinical immunotherapy was the dramatical loss of antiviral eYcacy even during a short-term in vitro selection of an epitope- The selection results in a "green-speciWc" cytolytic T lymphocyte line (CTLL) and in a "green-speciWc" population of memory CD8 T cells (CD8-T M ), respectively. (Bottom) a For preemptive therapy, the selected CD8 T cells are transferred to immunocompromised HSCT recipients infected (red virus symbol) on the same day. b For therapy, the selected CD8 T cells are transferred on day 6 after infection, a time when the virus has already disseminated from the portal of entry to target organs of CMV disease. DLI donor lymphocyte infusion, HSCT hematopoietic stem cell transplantation. The Xash symbol represents hematoablative treatment by total body -irradiation monospeciWc but polyclonal CTLL with still broad TCR V chain usage [17] . As shown in Fig. 3a , sorted IE1 epitope-speciWc CD8-T M proved to be 100-fold more eYcient in controlling mCMV infection than cells of a polyclonal CTLL of the same epitope-speciWcity after just three rounds of restimulation in cell culture. This was the case in spite of the fact that the functional avidity of the CTLL was actually higher due to the in vitro selection favoring cells with highaYnity TCRs (Fig. 3b) . The molecular basis for this rapid loss of in vivo function is not yet clear, but a change in migration and homing properties is likely.
Notably, in these models of acute CMV infection, CD4 T cells derived from CMV-immune donors did not exert any direct or indirect protective antiviral eVect upon adoptive transfer, which excludes them as eVector cells for use in immunotherapy protocols. It is important to emphasize that CD4 T cells "educated" in the absence of CD8 T cells-such as it occurs in long-term CD8 T cell-depleted [55] or genetically CD8 T-cell deWcient mice [56] -diVer essentially from CD4 T cells educated in the presence of CD8 T cells, in that they can mediate an indirect antiviral function. The molecular and immunoregulatory basis for this diVerent programming of CD4 T cells is still unexplored. Somewhat unexpected was the Wnding that CD4 T cells derived from CMV-immune donors did not even function as helper cells improving the eYcacy of CD8 T cell transfer. SpeciWcally, co-transfer of memory CD4 and CD8 T cells derived from the same donors in ratios of 0.25:1, 1:1, and 4:1 did not show any diVerence in the protective eYcacy against acute infection [11] . However, these Wndings do by no means exclude a role for CD4 T cell help in the maintenance of a protective CD8 T cell pool, a role suggested by clinical Wndings (reviewed in [4] ; see also the contribution by Müller and Mertens in this issue of MMI). One must consider the fact that in the murine HSCT models, CD4 T cells are endogenously generated in the course of lympho-hematopoietic reconstitution and thus may be involved in the long-term control of CMV. Of interest in this context is the recent Wnding that OX40 (CD134) costimulation promotes the persistence of mCMV-speciWc CD8 T cells by a CD4-dependent mechanism [57] .
Protective function of CD8 T cells is unrelated to epitope immunodominance
For a long time, it was implicitly understood that epitopes, which prime a quantitatively dominant immune response to natural infection-the so-called immunodominant epitopes-are the best candidates for use in adoptive immunotherapy or in a vaccine. In our view, having corrected this opinion is the most important contribution made by the In the BALB/c model, most of the known mCMV antigens were already tested in D. H. Spector's group for eliciting protection as a plasmid DNA vaccine and in our own group for priming of CD8 T cells that are protective in experimental immunotherapy (referenced in Table 1 ). Both approaches independently arrived at the conclusion that the protective potential of an epitope is independent of its immunodominance status; even epitopes, which barely prime an immune response in the context of infection, can be perfect for vaccination or adoptive immunotherapy. In fact, in the immunotherapy setting, we even believe to see a tendency to the favor of subdominant epitopes. In the BALB/c model, protective CTLL could be raised with all antigenic peptides tested, and in the vaccination approach only one epitope, namely M83, failed for unknown reason. In the C57BL/6 model, mCMV-primed CD8 T cells are in principle also protective in immunotherapy (R.H., unpublished observation), with a remarkable exception. CTLL as well as sorted CD8-T M speciWc for the D b -restricted antigenic peptide M45 985-HGIRNASFI-993 [59], although this is an epitope that is immunodominant in the acute immune response to mCMV [60] , completely failed in protection [61] . This failure was not caused by a functional anergy of the transferred CD8 T cells but could be attributed to the action of the viral immune evasion molecule m152/gp40 in the infected cells of the transfer recipients, since the same CD8 T cells protected against the deletion mutant mCMV-m152 [61] (for reviews see also reference Table 1 ) were puriWed from BALB/c spleen-derived, immunomagnetically enriched CD8 T cells by cytoXuorometric sorting using L d -Dimer-IE1 for epitope-speciWc TCR labeling. Adoptive transfer of 10 4 sorted cells was performed according to the preemptive immunotherapy protocol (see Fig. 1 ) using BALB/c recipients, but with no HSCT being performed. Throughout, intraplantar infection was done with 10 5 PFU of mCMV-WT, strain Smith. Infected cells were detected on day 12 in whole-organ sections of the adrenal (suprarenal) glands and in liver tissue sections by immunohistological black staining of the intranuclear IE1 protein (pp76/89) using the peroxidase-diaminobenzidine-nickel method. a, c Adrenal glands of the groups with no therapy or with therapy, respectively. b1, b2 Massive infection of the liver shown in an overview photograph and resolved to greater detail, respectively. The arrow in the overview photograph points to the viral plaque-like focus that is shown enlarged. d Absence of liver infection after immunotherapy. Bars represent 100 m. Reproduced from Refs. [17, 20] with permission by the Journal of Virology (American Society for Microbiology) and by Caister Academic Press, respectively [20] as well as the contribution by Doom and Hill in this issue of MMI).
This example is highly instructive and raises questions. First, it tells us that the myeloid lineage cells proposed to disseminate the virus from the portal of entry into the target tissues of disease (see above) are likewise susceptible to immune evasion mediated by m152/gp40, since, otherwise, M45-D b -speciWc CD8 T cells should have been protective in the model of preemptive therapy (recall Fig. 1a) . This is in accordance with the previous Wnding that viral immune evasion molecules are operative also in bone marrowderived dendritic cells [62] . Remarkably, M45-D b -speciWc CD8-T M remained functional for several months during viral latency when infectious virus was absent and peptide presentation prevented [61] . This may either mean that restimulation is not needed for the maintenance of CD8-T M pools or that restimulation occurs through unnoticed episodes of virus recurrence. A central question is how priming occurs in the face of immunoevasins, with crosspresentation of viral peptides by uninfected dendritic cells being a frequently discussed, possible answer (for reviews see [20] and the contribution by Martin et al. in this issue of MMI).
Concluding remarks
The murine model has shown that adoptive transfer of eVector or memory CD8 T cells is a promising option to control CMV infection and prevent CMV organ disease in immunocompromised recipients. Importantly, CD8 T cells cannot only prevent virus dissemination from the portal of entry to organ sites of CMV disease in a regimen of preemptive therapy but can also cope with an already established organ infection in a regimen of therapy. This holds true at least for an early stage of viral spread within tissue when the beneWt from preventing viral histopathology exceeds a possible immunopathology by cell death due to CD8 T cell eVector function.
Protection could be achieved whatever epitope was chosen, with one notable exception discussed above, and independent of the immunodominance shown by the corresponding CD8 T cells in the context of infection. By making use of a mutant virus in which the two H-2 d -restricted immunodominant epitopes (IDEs) IE1 and m164 were functionally deleted through point mutations in their respective C-terminal MHC anchor residues, a virus referred to as mCMV-IDE, a very recent study has shown that absence of IDE-speciWc cells in the donor CD8-T M population has no eVect on the recognition of target cells infected with the corresponding IDE-expressing revertant virus. Furthermore, deletion of IDEs also had no impact on the protection in adoptive transfer recipients, indicating that IDEs are dispensable and that CD8-T M speciWc for nonIDEs suYce for antiviral protection (Holtappels R et al., Subdominant T cell epitopes account for protection against cytomegalovirus independent of immunodomination. J Virol, in revision). From a clinical perspective, this work makes the important prediction that even major antigenic diVerences between the virus variant that has primed donor immunity and the virus variant infecting the HSCT recipient will not signiWcantly reduce the chances of immunotherapy. The antiviral eYcacy of CD8 T cells in adoptive transfer regimens may come as a surprise in the light of viral immunoevasins interfering with antigen presentation in the MHC class-I pathway (for reviews, see [20, 22] and the contribution by Doom and Hill in this issue of MMI). Whereas immunoevasins expressed by wild-type mCMV (mCMV-WT) were reported to completely prevent target cell lysis by CTL [63] , the inhibition was less complete when induction of interferon-in CD8 T cells was used for assessing antigen presentation and CD8 T cell stimulation [62] , which is in better accordance with the protective activity of CD8 T cells in adoptive immunotherapy. In addition, in early studies [64] reproduced in our laboratory (R.H. unpublished data) cytokines such as interferon-were shown to override the inhibition.
Memory CD8 T cells derived ex vivo from immune donors proved to be far better than a CD8 T cell line of the same epitope-speciWcity, even if the line is selected shortterm and still polyclonal with broad TCR chain usage and higher functional avidity (see also the accompanying paper by Böhm et al. in this issue of MMI). Recent translational research has already conWrmed the high eYcacy of memory CD8 T cells [18] , but a side-by-side comparison of sorted CD8-T M and CTLL of the same epitope-speciWcity was, of course, not feasible in human studies. Thus, the murine model has provided "proof of concept" for the superiority of ex vivo puriWed CD8 T cells in the immunotherapy of CMV infection.
